Ardelyx Showcases Key Findings for XPHOZAH in Kidney Disease
Ardelyx, Inc. (Nasdaq: ARDX), based in Waltham, Massachusetts, is on a mission to bring innovative treatments to individuals facing significant health challenges. Recently, the company announced their plan to present important data related to XPHOZAH® (tenapanor) at the esteemed American Society of Nephrology's Kidney Week event. This year, the event will take place from October 24-27, showcasing advancements in the management of chronic kidney disease (CKD).
What is XPHOZAH?
XPHOZAH is a pioneering phosphate absorption inhibitor that has gained approval from the U.S. Food and Drug Administration. It specifically targets adults with CKD who are on dialysis, providing an essential addition for patients who do not respond adequately to phosphate binders or experience adverse effects from them. Administered as a single tablet taken twice daily, XPHOZAH operates through a unique mechanism that disrupts phosphate absorption in the intestines.
Presentation Highlights at Kidney Week
During the Kidney Week, Ardelyx will share compelling insights through two significant poster presentations. One study emphasizes the association between sustained phosphate reduction with tenapanor and decreased levels of fibroblast growth factor 23 in patients experiencing hyperphosphatemia while on dialysis. The second poster demonstrates that the efficacy and tolerability of tenapanor remain consistent when incorporated alongside different phosphate binders.
Innovative Management Discussion
In addition to the poster presentations, Ardelyx will sponsor an engaging Exhibitor Spotlight entitled “A Different Perspective on Hyperphosphatemia Management: Evaluating Current Strategies.” This session, occurring on October 25, will feature Dr. Steven Fishbane, who will delve deeper into the benefits of XPHOZAH.
Understanding Hyperphosphatemia
Hyperphosphatemia is a critical condition characterized by elevated phosphate levels in the blood, affecting countless patients with chronic kidney disease undergoing maintenance dialysis. As kidney function decreases, the body struggles to eliminate excess phosphate, leading to complications that can severely impact overall health. Therefore, managing phosphate levels effectively is imperative, as recommended by KDIGO guidelines.
Safety Information for XPHOZAH
While XPHOZAH offers vital benefits for managing phosphate levels, it also comes with essential safety considerations. Specifically, it is contraindicated in pediatric patients under six years of age and those with known gastrointestinal obstructions. Furthermore, severe diarrhea was noted as the most common adverse reaction, occurring in a significant percentage of clinical trial participants. Thus, patients are advised to discontinue XPHOZAH if they experience severe diarrhea during treatment.
About Ardelyx and Its Commitment
Ardelyx is dedicated to discovering, developing, and commercializing groundbreaking medicines like XPHOZAH and its other product, IBSRELA® (tenapanor). With their commitment to addressing unmet medical needs, Ardelyx has formed various collaborations to expand the reach of its products beyond the U.S., including partnerships in Japan and China.
Investor and Media Inquiries:
Caitlin Lowie
Contact: clowie@ardelyx.com
Frequently Asked Questions
What is XPHOZAH and its purpose?
XPHOZAH is a first-in-class phosphate absorption inhibitor approved for reducing serum phosphorus in adults with CKD on dialysis.
Where will Ardelyx present the data?
The data will be presented at the American Society of Nephrology's Kidney Week, an event dedicated to advancements in nephrology.
What are the side effects of XPHOZAH?
The most common side effect reported is diarrhea, which affected a notable percentage of patients in clinical trials.
Is XPHOZAH suitable for all patients with CKD?
No, it is contraindicated in pediatric patients under six and those with specific gastrointestinal conditions.
What does Ardelyx aspire to achieve?
Ardelyx aims to provide innovative treatments that meet significant unmet medical needs through their products like XPHOZAH and IBSRELA.
